Open Access

Axillary lymph node dose with tangential whole breast radiation in the prone versus supine position: a dosimetric study

  • Kara Lynne Leonard1Email author,
  • David Solomon1,
  • Jaroslaw T Hepel2,
  • Jessica R Hiatt2,
  • David E Wazer1, 2 and
  • Thomas A DiPetrillo1, 2
Contributed equally
Radiation Oncology20127:72

DOI: 10.1186/1748-717X-7-72

Received: 13 January 2012

Accepted: 30 April 2012

Published: 18 May 2012

Abstract

Background

Prone breast positioning reduces skin reaction and heart and lung dose, but may also reduce radiation dose to axillary lymph nodes (ALNs).

Methods

Women with early stage breast cancer treated with whole breast irradiation (WBI) in the prone position were identified. Patients treated in the supine position were matched for treating physician, laterality, and fractionation. Ipsilateral breast, tumor bed, and Level I, II, and III ALNs were contoured according to the RTOG breast atlas. Clips marking surgically removed sentinel lymph nodes (SLN)s were contoured. Treatment plans developed for each patient were retrospectively analyzed. V90% and V95% was calculated for each axillary level. When present, dose to axillary surgical clips was calculated.

Results

Treatment plans for 46 women (23 prone and 23 supine) were reviewed. The mean V90% and V95% of ALN Level I was significantly lower for patients treated in the prone position (21% and 14%, respectively) than in the supine position (50% and 37%, respectively) (p < 0.0001 and p < 0.0001, respectively). Generally, Level II & III ALNs received little dose in either position. Sentinel node biopsy clips were all contained within axillary Level I. The mean V95% of SLN clips was 47% for patients treated in the supine position and 0% for patients treated in the prone position (p < 0.0001). Mean V90% to SLN clips was 96% for women treated in the supine position but only 13% for women treated in the prone position.

Conclusions

Standard tangential breast irradiation in the prone position results in substantially reduced dose to the Level I axilla as compared with treatment in the supine position. For women in whom axillary coverage is indicated such as those with positive sentinel lymph node biopsy who do not undergo completion axillary dissection, treatment in the prone position may be inappropriate.

Keywords

Breast cancer Prone Axillary lymph nodes Radiation ACOSOG Z0011

Background

The eight-year results of the ACOSOG Z0011 study evaluating locoregional recurrence after sentinel lymph node dissection (SLND) with or without axillary lymph node dissection (ALND) in patients with positive sentinel lymph nodes suggest that completion ALND may be unnecessary for selected early stage breast cancer patients [1, 2]. Patients treated on ACOSOG Z0011 received whole breast irradiation (WBI) with tangents in the supine position. Whole breast irradiation provides moderate radiation dose to the Level I and II axillary lymph nodes (ALN)s and to the region of the sentinel node [313]. If one considers that modest radiation doses to the axilla have clinical impact, the potentially practice-altering implications of ACOSOG Z0011 may reflect the importance of adequate dosing of these ALNs for sentinel node positive patients who have not had axillary dissection.

Recently, prone breast positioning for WBI has become more popular in efforts to decrease radiation dose to the heart and lungs and to decrease acute skin reaction in women with pendulous breasts [9, 1417] while maintaining acceptable long-term outcomes [18]. Treatment planning studies have demonstrated the dosimetric benefits of prone breast irradiation for all women, regardless of breast size [19]. Prone positioning increases the anatomic distance of the breast from the heart and lungs, eliminates the bolus effect created by the inframammary fold, and improves dose homogeneity as compared to WBI in the prone position. Recent work has shown decreased coverage of the ALNs in the prone position when treatment plans were created for each patient in both the prone and supine position [9]. The current work explores dosing to axillary lymph nodes in patients thought to be ideal candidates for prone positioning.

Methods

Forty-six women with early stage breast cancer treated from 2009–2011 in the Departments of Radiation Oncology at our institution with standard tangential WBI in the prone or supine were identified. The 23 patients treated in the prone position were identified as ideal candidates for treatment in the prone position prior to or at the time of simulation for a variety of reasons including large breast size (n = 9), to limit lung dose (n = 11), or to limit heart dose (n = 3). Those treated prone for large breast size had a breast volume of 1000 mL or greater, those treated prone to limit lung dose would have had 2.5 cm or greater of cross-sectional lung included within a standard tangent, and those treated prone to limit heart dose had an anteriorly located left anterior descending (LAD) artery. Twenty-three patients treated in the supine position consecutively during the same time period (2009 – 2011) were chosen for comparison and matched for treating physician, laterality, and fractionation (conventional vs. Canadian fractionation [20]). All patients underwent Computed Tomography (CT) - based simulation using a Philips Brilliance Big Bore 16-slice CT scanner (Philips Healthcare, Andover, MA). Patients treated prone were simulated using the Bionix Prone Breast System (Bionix Radiation Therapy, Toledo, OH) and patients treated supine were simulated using the Accufix Quest Breast Board (Q-Fix Systems, Wyckoff, NJ). Three dimensional (3D) treatment planning for all patients was performed using the Pinnacle3 (version 8.0m, Philips Medical Systems, Cleveland, OH) treatment planning system. Conventional and prone breast tangential fields were designed to encompass the whole breast while minimizing dose to lung and heart without special attention to ALN coverage as confirmed by the treating physician. No patients were treated with “high tangents.”

Planning CT scans were retrospectively contoured to identify ipsilateral breast tissue, tumor bed, and Level I, II, and III ALNs according to the anatomic boundaries set by the Radiation Therapy Oncology Group (RTOG) contouring atlas [21], as shown in Figure 1. Table 1 delineates the boundaries of the levels in all 6 directions. When present, clips marking sentinel lymph nodes (SLN) removed during sentinel node biopsy were also contoured. Ipsilateral breast and ALN Level I-III volumes were compared between the two groups using the t-test.
https://static-content.springer.com/image/art%3A10.1186%2F1748-717X-7-72/MediaObjects/13014_2012_Article_621_Fig1_HTML.jpg
Figure 1

Axial and coronal images of Level I contoured (violet) for a patient treated in the (a) prone and (b) supine position.

Table 1

Anatomic boundaries of the ipsilateral breast and axillary lymph node Levels I-III as defined by the Radiation Therapy Oncology Group (RTOG) contouring atlas [1]

 

Cranial

Caudal

Medial

Lateral

Anterior

Posterior

Breast

Clinical reference and second rib insertion

Clinical reference and loss of CT apparent breast

Sternal-rib junction

Clinical reference and mid axillary line. Excludes latissimus dorsi

Skin

Excludes pectoralis muscles, chestwall muscles, ribs

Level I

Axillary vessels crossing lateral edge of pectoralis minor

Pectoralis major insertion into ribs

Axillary vessels crossing lateral edge of pectoralis minor

Medial border of latissimus dorsi

Plane defined by the anterior surface of pectoralis major and latissimus dorsi

Anterior surface of subscapularis

Level II

Axillary vessels crossing medial edge of pectoralis minor

Axillary vessels crossing lateral edge of pectoralis minor

Medial border of pectoralis minor

Lateral border of pectoralis minor

Anterior surface of pectoralis minor

Ribs and intercostal muscles

Level III

Pectoralis minor insertion on corocoid process

Axillary vessels crossing medial edge of pectoralis minor

Thoracic inlet

Medial border of pectoralis minor

Posterior surface of pectoralis major

Ribs and intercostal muscles

Treatment plans for each patient were retrospectively analyzed to evaluate dose to the tumor bed, breast, and individual nodal levels. The mean dose to the ipsilateral breast as well as the volume of breast tissue and tumor bed receiving 95% (V95%) of the prescribed dose were calculated. The mean dose and the volume receiving 50% (V50%), 90% (V90%), and 95%, of the prescribed dose were then calculated for each axillary level. Dose to axillary surgical clips was similarly calculated, when applicable. Mean dose, V90%, V95% of axillary Level I were compared between those treated in the prone position and those treated in the supine position using a two-tailed unpaired t-test for difference of means. For Level I, the relative dose-volume histograms (DVH) were generated for all patients and the mean DVHs were compared among the prone and supine groups.

Results

Table 2 provides patient characteristics for the prone and supine cohorts. In general, patients treated in the prone position were younger. The mean ipsilateral breast volumes and axillary Level I, II, and III nodal volumes (and standard deviations) are also shown in Table 2. As expected, breast volumes tended to be larger in the prone position than in the supine position, but this difference did not reach statistical significance. There was no difference in volumes contained within the axillary nodal levels between the two groups.
Table 2

Summary of patient characteristics

  

Supine (n= 23)

Prone (n= 23)

Comparison (two-tailed unpaired t-test)

 

Mean Age (y) ± SD*

65 ± 12

57 ± 9

 
 

Side: Left/Right

13/10

13/10

 
 

Mean breast volume (cm3) ± SD

841 ± 369

793 ± 462

p = 0.70 (CI= -200 to 296)

T Stage

Tis

7

5

 
 

T1

12

17

 
 

T2

4

1

 

N Stage

N0

21

21

 

N1

2

2

 

Dissection Status:

No nodal biopsy

5

6

 
 

Sentinel node biopsy

18

15

 
 

Completion axillary dissection

0

2

 

Radiation Dose

46 Gy in 23 fractions

8

8

 
 

42.5 Gy in 16 fractions

9

9

 
 

50-50.4 Gy in 25-28 fractions

6

6

 

Mean Axillary Volume

Level I (cm3) ± SD

106 ± 38

98 ± 35

p = 0.46 (CI = -30 to 14)

 

Level II (cm3) ± SD

21 ± 6

24 ± 7

 

Level III (cm3) ± SD

9 ± 3

10 ± 5

p = 0.13 (CI = -0.87 to 6.9)

    

p = 0.42 (CI = -3.5 to 1.5)

* SD = standard deviation; CI = Confidence interval.

Doses (and standard deviations) delivered to the ipsilateral breast, tumor bed, and all axillary levels are provided in Table 3a. Mean breast dose and V95% of ipsilateral breast and tumor bed did not differ significantly between those treated in the prone position and those treated in the supine position. Only axillary Level I received appreciable dose in both groups of patients. Generally, Level II & III ALNs did not receive a significant portion of prescribed dose in either position.
Table 3

Summary of calculated volume and dose to (a) ipsilateral breast and tumor bed, to (b) axillary levels I, II, and III and to (c)sentinel lymph node (SLN) clips

a) Dose to ipsilateral breast and tumor bed

  

Supine (n = 23)

Prone (n= 23)

Comparison (two-tailed unpaired t-test)

Ipsilateral breast mean dose (%) ± SD*

 

96 ± 3.8

95 ± 1.8

p = 0.26 (CI†† = -0.77 to2.8)

V95% ipsilateral breast

 

77 ± 6.5

74 ± 5.3

p = 0.09 (CI = -0.52 to 6.5)

V95% tumor bed

 

99 ± 1.7

98 ± 4.6

p = 0.33 (CI = -1.1 to 3.1)

b) Dose to axillary volumes

 

Mean dose (%) ± SD

Level I

66 ± 20

36 ± 30

p< 0.0001 (CI =15 to 45)

 

Level II

6 ±15

3 ± 3

 
 

Level III

3 ± 2

< 1 ± 0.4

 

Mean V95% ± SD

Level I

37 ± 18

14 ± 19

p < 0.0001 (CI = 12 to 34)

 

Level II

0

0

 
 

Level III

0

0

 

Mean V90% ± SD

Level I

50 ± 20

21 ± 25

p< 0.0001 (CI = 16 to 43)

 

Level II

1 ± 5

0

 
 

Level III

0

0

 

Mean V50% ± SD

Level I

67 ± 19

35 ± 33

 
 

Level II

5 ± 17

< 1 ± 2

 
 

Level III

0

0

 

c) Dose to sentinel lymph node (SLN ) clips

 
  

Supine ( n = 9)

Prone ( n = 7)

 

SNB clips in treatment field

 

9

2

 

V95% SLN clips ± SD

 

47 ± 43

0 ± 0

p<0.0001 (95% CI =29 to 65)

SLN clips receiving > 90% dose

 

8

1

 

Mean dose to SLN clips (%) ± SD

 

95 ± 5

43 ± 34

 

*SD = standard deviation; SLN = sentinel lymph node; ††CI = confidence interval.

Within each group, there was substantial variation in the dose coverage of axillary Level I. Among women treated in the prone position, V95% was less than 10% in 14 women and was 0% in 6 women. Figure 2 compares the mean Level I DVH for the prone and supine groups. The mean dose to Level I was 36% of prescription for patients treated in the prone position, significantly less than the 66% of prescription for patients treated in the supine position (p < 0.0001; 95% confidence interval = 15% to 45%). Mean V95% was lower in women treated in the prone position as compared to women treated in the supine position (14% vs. 37%; p < 0.0001; 95% confidence interval = 12% to 34%).
https://static-content.springer.com/image/art%3A10.1186%2F1748-717X-7-72/MediaObjects/13014_2012_Article_621_Fig2_HTML.jpg
Figure 2

Comparison of mean DVH data for patients treated in the prone and supine position.

Sixteen patients (seven treated prone and nine treated supine) had axillary surgical clips placed at the time of SLN biopsy; all of the clips were located within axillary Level I. Only two of the seven patients treated in the prone position had clips within the tangential treatment field. However, all SLN clips in patients treated in the supine position were within the treatment field. As shown in Table 3c, mean V95% of SLN clips was 0% for the seven patients treated in the prone position. Mean V95% of SLN clips was 47% among patients treated in the supine position. The difference in mean V95% between the two groups was statistically significant (p < 0.0001; 95% confidence interval = 29% to 65%). At least 90% of prescribed dose was delivered to the clips in eight of nine patients treated supine (mean V90% = 96%), but in only one of seven patients treated prone (mean V90% = 13%).

Discussion

The recently published eight-year results of the American College of Surgeons Oncology Group (ACOSOG) Z0011 study showed no difference in axillary failure rates or overall survival in women with cT1-2 cN0 breast cancer with one or two positive sentinel nodes randomized to undergo no further axillary surgery versus completion axillary dissection [1, 2]. The locoregional control was excellent (1.8% failure) despite suspected residual disease in approximately 40% of these women. Per protocol, women in this study received adjuvant radiation therapy with standard tangential irradiation. Although there has been debate surrounding the contribution of radiation therapy to axillary control in these women, this was likely due to sterilization of micrometastatic disease by tangential radiation therapy. These findings have strong implications for the importance of adjuvant radiation therapy to provide dose to the lower axilla in women with positive sentinel lymph nodes who will not undergo completion axillary dissection. In fact, regional nodal irradiation has also been associated with improved survival [22], and improvements in locoregional control have translated into improvements in overall survival with extended follow-up [23].

Prone breast irradiation provides clear benefits in reducing skin toxicity for large breasted women and in reducing heart and ipsilateral lung dose for patients with unfavorable thoracic anatomy [9, 1418]. The present investigation suggests that axillary nodal coverage should also be considered when making the decision to treat women in the prone versus supine position. The data presented in this study suggest that irradiation in the prone position does not allow for the same coverage of axillary tissue as does irradiation in the supine position.

Although the classic anatomic boundaries of the axilla are well defined, the clinically relevant borders are not. There is substantial variation in definition of boundaries of the axilla used in radiotherapy treatment as outlined in Table 4. For the purpose of standardizing the borders of the axilla, the RTOG published a contouring atlas [21]. Perhaps contrary to classic teaching, recent literature (including the present study) suggests that standard tangential whole breast irradiation delivers the prescribed dose to only a portion of Level I of the axilla, particularly as defined by the RTOG. In the present study, only 37% of the Level I volume received 95% of the dose with standard tangential irradiation. It is not clear whether this level of coverage delivers sufficient dose for therapeutic treatment of axillary lymph nodes. Studies demonstrating similar coverage of axillary Level I with standard tangents have suggested that such coverage does not provide adequate doses to control residual microscopic disease in the axilla [3, 7]. The present study suggests that the area of the axilla receiving fully dose (90-95% of the prescribed dose) may contain the microscopic disease. In fact, the clinically important target tissue in the axilla has not yet been clearly defined. The 98% locoregional control seen in ACOSOG Z0011 with SNLD alone suggests that standard tangential fields encompass the clinically relevant nodal tissue.
Table 4

Review of the literature reporting boundaries of and dose to axillary Level I volumes and/or clips in patients undergoing tangential radiation therapy as part of breast conservation therapy

Study

Patients (n)

Method

Axillary surgery

Axillary clips (n)

Borders of axillary Level I

Dose to Level I

Krasin et al.[3]

25

2D sim/3D analysis

ALND*

16

Not listed

Mean dose = 32 Gy (63.5%)

Aristei et al.[4]

35

2D sim/3D analysis

ALND

35

Caudal border: Inferior clip

D90% = 6.75 Gy

     

Cranial border: Axillary vein and 2nd clip

 
     

Medial border: Lateral border of pectoralis minor

 
     

Lateral border: Axillary vein

 
     

Posterior border: Latissimus dorsi

 

Takeda et al.[5]

44

2D sim/3D analysis

ALND

44

Caudal border: Clip in latissimus dorsi at inferior level of dissection

Median V80% = 30.5%

     

Cranial border: Clip in the latissimus dorsi at level of axillary vein

 
     

Posterior border: Clip in adjacent to subscapularis vein

 

Orecchia et al.[6]

15

3D CRT

SNB††

15

Caudal border: SNB clip

Mean dose = 48.7%

     

Cranial border Manubrium

± 22%

 

35

3D CRT

SNB

N/A

Caudal border: Between 4th and 5th ribs

V95% = 51% ± 16%

Reznik et al.[7]

    

Cranial border: Axillary vein

Mean dose = 66% ± 13%

     

Medial border: Pectoralis minor

 

Reed et al.[8]

50

3D CRT

32 SNB

50

Caudal border: Latissiumus dorsi and clavipectoral-lattisimus fascia

Mean V95% = 55% Median V95% = 53%

   

18 ALND

 

Cranial border: Most inferior axial image of axillary artery/vein

 
     

Medial border: Pectoralis minor

 
     

Lateral border: Medial aspect of pectoralis seratus

 
     

Anterior border: Pectoralis minor

 
     

Posterior border: Latissimus dorsi and subscapularis

 

Alonso-Basanta et al.[9]

20

3D CRT

Not reported

N/A

Caudal border: Origin of pectoralis minor 3rd – 5th ribs

V95% < 60%

     

Cranial border: Pectoralis minor insertion of the coracoid process

Prone: Mean dose = 11.2 Gy

     

Medial border: Pectoralis minor

Supine: Mean dose = 21 Gy

     

Lateral border: Latissimus dorsi

 
     

Posterior border: Latissimus dorsi

 

Schlembach et al.[10]

105

3D CRT

65 SNB

105

Surgical clips

85% of clips in the field

      

Mean dose to clips = 98%

   

39 ALND

   

McCormick et al.[11]

45

2D

ALND

45

Surgical clips

38% of clips in field

Chung et al.[12]

36

2D or 3D CRT

SNB

36

Surgical clips

94% of clips in field

Present study

46

3D CRT

SNB

7 prone

RTOG Atlas [20]

Prone: V95% = 14%

    

9 supine

 

Mean dose = 36% ± 31%

      

Mean dose to clips = 43%

      

Supine: V95% = 37% (supine)

      

Mean dose = 66% ± 20%

      

Mean dose to clips = 95%

*ALND = Axillary lymph node dissection; 3DCRT = Three dimensional conformal radiation therapy; ††SNB = Sentinel node biopsy.

The location of clips placed during SNLD may represent the area at highest risk of harboring metastatic disease after SNLD alone. Certainly, we know that the sentinel node is the most likely to contain breast cancer metastases. The neighboring nodes may represent the next echelon for metastatic spread. Despite suboptimal coverage of the entire nodal volume, standard tangents provide substantial dose to the clips placed to mark the location of the sentinel lymph node as shown in this study as well as others [8, 10, 12]. However, for women treated in the prone position, the area marked by SNLD clips receives minimal radiation dose. This raises concern that treatment in the prone position may provide suboptimal coverage of the most clinically important axillary nodal areas.

The study by Stegman et al., which showed a 5-year regional control rate of 98.4% in 245 patients treated with WBI in the prone position demonstrates that prone irradiation provides adequate adjuvant treatment for the pathologically negative axilla and for the positive axilla that has undergone a full Level 1, 2 axillary lymph node dissection [18]. This excellent axillary control rate is expected in a population of women comprised of 15% of patients with DCIS and 65% of patients with pN0 disease. Importantly, all women with positive lymph nodes in the Stegman study underwent Level 1, 2 axillary lymph node dissection. The undissected node-positive population in the ACOSOG Z0011 is at substantially higher risk for regional failure and likely receives substantial benefit from standard tangential irradiation.

Results similar to ours were published by Alonso-Basanta et al., who reported on twenty patients simulated in both the prone and supine position [9]. The mean dose to the axilla was 11.2 Gy when patients were simulated in the prone position and 21 Gy when the same patients were simulated in the supine position. The authors stated that alternative positioning was warranted in eight of the twenty patients for anatomic reasons (i.e., breast size, lung dose), while in the present study, all twenty-three patients treated prone were determined to be ideal candidates for prone positioning by the treating radiation oncologist. Thus, the current investigation includes patients in whom such a dosimetric evaluation is most critical. Moreover, the present study includes the novel finding that tangential irradiation in the supine position provides significantly better coverage of sentinel lymph node tissue than tangential irradiation in the prone position.

The limitations of the present study include a small sample size and the inherent sample bias associated with retrospective trial design. Additionally, only a small number of patients had SNLD clips placed, limiting the analysis of radiation dose delivery to axillary clips. While care was taken to choose an appropriate supine match for each prone patient, differences may inherently exist between the two groups. Although there was no significant difference in mean breast size or mean axillary volume between the two groups, other differences may exist that could bias the results. For example, patients in the prone group are slightly younger than patients in the supine group.

Conclusion

Standard tangential breast irradiation in the prone position results in substantially reduced dose to the Level I axilla as compared with treatment in the supine position. For women in whom axillary coverage is indicated such as those with positive sentinel lymph node biopsy who do not undergo completion axillary dissection, treatment in the prone position may be inappropriate. For women with DCIS or those with a negative sentinel node biopsy, treatment in the prone position does result in good coverage of target breast tissue.

Abbreviations

ALN: 

Axillary lymph node

WBI: 

Whole breast irradiation

SLN: 

Sentinel lymph node

SLND: 

Sentinel lymph node dissection

ALND: 

Axillary lymph node dissection

CT: 

Commuted tomography

RTOG: 

Radiation Therapy Oncology Group

V90%

Volume receiving 90% of the dose

V50%

Volume receiving 50% of the dose

V95%

Volume receiving 95% of the dose

DVH: 

Dose volume histogram.

Declarations

Authors’ Affiliations

(1)
Department of Radiation Oncology, Tufts Medical Center
(2)
Department of Radiation Oncology, Rhode Island Hospital, Warren Alpert School of Medicine of Brown University

References

  1. Giuliano AE, McCall L, Beitsch P, et al.: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010, 252: 426-433.PubMed
  2. Giuliano AE, Hunt KK, Ballman KV, et al.: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011, 305: 569-575. 10.1001/jama.2011.90View ArticlePubMed
  3. Krasin M, McCall A, King S, et al.: Evaluation of a standard breast tangent technique: A dose-volume analysis of tangential irradiation using three-dimensional tools. Int J Radiat Oncol Biol Phys 2000, 47: 327-333. 10.1016/S0360-3016(00)00449-1View ArticlePubMed
  4. Aristei C, Chionne F, Marsella AR, et al.: Evaluation of level I and II axillary nodes included in the standard breast tangential fields and calculation of the administered dose: Results of a prospective study. Int J Radiat Oncol Biol Phys 2001, 51: 69-73.View ArticlePubMed
  5. Takeda A, Shigematsu N, Ikeda T, et al.: Evaluation of novel modified tangential irradiation technique for breast cancer patients using dose–volume histograms. Int J Radiat Oncol Biol Phys 2004, 58: 1280-1288. 10.1016/j.ijrobp.2003.10.010View ArticlePubMed
  6. Orecchia R, Huscher A, Leonardi MC, et al.: Irradiation with standard tangential breast fields in patients treated with conservative surgery and sentinel node biopsy: Using a three-dimensional tool to evaluate the first level coverage of the axillary nodes. Br J Radiol 2005, 78: 51-54. 10.1259/bjr/29242407View ArticlePubMed
  7. Reznik J, Cicchetti MG, Degaspe B, et al.: Analysis of axillary coverage during tangential radiation therapy to the breast. Int J Radiat Oncol Biol Phys 2005, 61: 163-168. 10.1016/j.ijrobp.2004.04.065View ArticlePubMed
  8. Reed DR, Lindsley SK, Mann GN, et al.: Axillary lymph node dose with tangential breast irradiation. Int J Radiat Oncol Biol Phys 2005, 61: 358-364. 10.1016/j.ijrobp.2004.06.006View ArticlePubMed
  9. Alonso-Basanta M, Ko J, Babcock M, et al.: Coverage of axillary lymph nodes in supine vs. prone breast radiotherapy. Int J Radiat Oncol Biol Phys 2009, 73: 745-751. 10.1016/j.ijrobp.2008.04.040View ArticlePubMed
  10. Schlembach PJ, Buchholz TA, Ross MI, et al.: Relationship of sentinel and axillary Level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys 2001, 51: 671-678. 10.1016/S0360-3016(01)01684-4View ArticlePubMed
  11. McCormick B, Botnick M, Hunt M, et al.: Are the axillary lymph nodes treated by standard tangent breast fields? J Surg Oncol 2002, 81: 12-16. 10.1002/jso.10148View ArticlePubMed
  12. Chung MA, DiPetrillo T, Hernandez S, et al.: Treatment of the axilla by tangential breast radiotherapy in women with invasive breast cancer. Am J Surg 2002, 184: 401-402. 10.1016/S0002-9610(02)01013-9View ArticlePubMed
  13. Goodman RL, Grann A, Saracco P, et al.: The relationship between radiation fields and regional lymph nodes in carcinoma of the breast. Int J Radiat Oncol Biol Phys 2001, 50: 99-105. 10.1016/S0360-3016(00)01581-9View ArticlePubMed
  14. Merchant TE, McCormick B: Prone position breast irradiation. Int J Radiat Oncol BiolPhys 1994, 30: 197-203.View Article
  15. Formenti SC, Gidea-Addeo D, Goldberg JD, et al.: Phase I–II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue. J Clin Oncol 2007, 25: 2236-2242. 10.1200/JCO.2006.09.1041View ArticlePubMed
  16. Griem KL, Fetherston P, Kuznetsova M, et al.: Three-dimensional photon dosimetry: a comparison of treatment of the intact breast in the supine and prone position. Int J Radiat Oncol Biol Phys 2003, 57: 891-899. 10.1016/S0360-3016(03)00723-5View ArticlePubMed
  17. Kirby AM, Evans PM, Donovan EM, et al.: Prone versus supine positioning for whole and partial-breast radiotherapy: A comparison of non-target tissue dosimetry. Radiother Oncol 2010, 96: 178-184. 10.1016/j.radonc.2010.05.014View ArticlePubMed
  18. Stegman LD, Beal KP, Hunt MA, et al.: Long-term clinical outcomes of whole-breast irradiation delivered in the prone position. Int J Radiat Oncol Biol Phys 2007, 68: 73-81. 10.1016/j.ijrobp.2006.11.054View ArticlePubMed
  19. Ramella S, Trodella L, Ippolito E, et al.: Whole-Breast Irradiation: A Subgroup Analysis of Criteria to Stratify for Prone Position Treatment. Med Dosim 2011. Epub ahead of print
  20. Whelan T, Pignol JP, Levine MN, et al.: Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010, 362: 513-520. 10.1056/NEJMoa0906260View ArticlePubMed
  21. Xa LI, Tai A, Arthur DW, et al.: Variability of target and normal structure delineation for breast cancer radiotherapy: An RTOG multi-institutional and multiobserver study. Int J Radiat Oncol Biol Phys 2009, 73: 944-951. 10.1016/j.ijrobp.2008.10.034View Article
  22. Whelan TJ, Olivotto I, Acherman I, et al.: NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in eraly breast cancer. J Clin Oncol [abstract] 2011., 29S: abstr LBA 1003
  23. Clarke M, Collins R, Darby S, Early Breast Cancer Trialists Collaborative Group (EBCTCG), et al.: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011, 366: 2087-2106.

Copyright

© Leonard et al.; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement